Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358578 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,306
- Enrollment target
NCT01358578: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT01358578 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,306 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01358578, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,306 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
Primary Outcome
A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis
Interventions
- DRUG Placebo
- DRUG etanercept
- DRUG secukinumab (AIN457)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,306 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
What the finished NCT01358578 record still lists
NCT01358578 is an interventional study that assigns participants to a tested intervention. Its 1,306 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01358578 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01358578 about?
NCT01358578 is a clinical study titled "Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis". This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
What is the current status of trial NCT01358578?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,306 participants. The study started on 2011-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01358578?
The interventions under investigation include: Placebo (DRUG), etanercept (DRUG), secukinumab (AIN457) (DRUG).
Who is sponsoring clinical trial NCT01358578?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01358578's enrollment target sits among peer trials
1,306 188th of 2000 higher than 1,813 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06517901 · 1,306 participants · NA
Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
- NCT04171323 · 1,305 participants · NA
The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
- NCT06136624 · 1,310 participants · Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- NCT06556433 · 1,312 participants · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia